Literature DB >> 2065499

Reversion of the steroid-induced decrease of serum osteocalcin with sodium fluoride.

H Rico1, J A Cabranes, E R Hernandez, A Barabash, P Romero.   

Abstract

Osteopenia observed in corticotherapy is due, among other causes, to a decrease in bone formation as can be shown by a steroid-induced osteocalcin decrease. Although various treatments have been proposed there is no agreement as to which one is the best. Two such treatments, sodium fluoride and vitamin D administration increase osteocalcin levels. We treated a group of 12 patients under corticoid therapy (mean dose 16 mg per day) with 50 mg/day p.o. sodium fluoride, and determined osteocalcin levels before and two weeks after sodium fluoride treatment. Similarly, another group of 9 patients with a similar mean steroid dose was treated with 0.5 micrograms/day of 1 alpha (OH)2D3 in order to assess the effect of this vitamin on osteocalcin and to determine which was the best treatment. Both groups were compared with respective control groups. A significant osteocalcin increase was observed in the control groups (p less than 0.001); similar significance was observed in the sodium fluoride group, whereas a lower significance (p less than 0.01) was observed in the vitamin D group. These results suggest that sodium fluoride could be more effective than vitamin D in the treatment of steroid-induced osteopenia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2065499     DOI: 10.1007/BF02208025

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  22 in total

1.  Osteoporosis in Cushing's syndrome.

Authors:  A IANNACCONE; J L BABRILOVE; S A BRAHMS; L J SOFFER
Journal:  Ann Intern Med       Date:  1960-03       Impact factor: 25.391

Review 2.  Steroid osteoporosis.

Authors:  I R Reid
Journal:  Calcif Tissue Int       Date:  1989-08       Impact factor: 4.333

3.  Stimulation of undermineralized matrix formation by 1,25 dihydroxyvitamin D3 in long bones of rats.

Authors:  J M Hock; M Gunness-Hey; J Poser; H Olson; N H Bell; L G Raisz
Journal:  Calcif Tissue Int       Date:  1986-02       Impact factor: 4.333

4.  1,25-dihydroxyvitamin D3 increases serum levels of the vitamin K-dependent bone protein.

Authors:  P A Price; S A Baukol
Journal:  Biochem Biophys Res Commun       Date:  1981-04-15       Impact factor: 3.575

5.  Corticosteroid-induced osteopenia and vitamin D metabolism. Effect of vitamin D2, calcium phosphate and sodium fluoride administration.

Authors:  H Rickers; A Deding; C Christiansen; P Rødbro; J Naestoft
Journal:  Clin Endocrinol (Oxf)       Date:  1982-04       Impact factor: 3.478

6.  Suggestion of a deficient osteoblastic function in diabetes mellitus: the possible cause of osteopenia in diabetics.

Authors:  H Rico; E R Hernandez; J A Cabranes; F Gomez-Castresana
Journal:  Calcif Tissue Int       Date:  1989-08       Impact factor: 4.333

7.  Low serum osteocalcin levels in glucocorticoid-treated asthmatics.

Authors:  I R Reid; G E Chapman; T R Fraser; A D Davies; A S Surus; J Meyer; N L Huq; H K Ibbertson
Journal:  J Clin Endocrinol Metab       Date:  1986-02       Impact factor: 5.958

8.  Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases.

Authors:  T R Dykman; K M Haralson; O S Gluck; W A Murphy; S L Teitelbaum; T J Hahn; B H Hahn
Journal:  Arthritis Rheum       Date:  1984-12

9.  Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide.

Authors:  F Santos; M J Smith; J C Chan
Journal:  Am J Dis Child       Date:  1986-02

10.  Effect of 1alpha-hydroxycholecalciferol in senile osteoporosis and in bone loss following prednisone treatment.

Authors:  O H Sorensen; B Lund; T H Friis; L Hjorth; I Reimann; I Kjaer; R B Andersen
Journal:  Isr J Med Sci       Date:  1977-03
View more
  1 in total

1.  Bone loss after cardiac transplantation: effects of calcium, calcidiol and monofluorophosphate.

Authors:  E Meys; F Terreaux-Duvert; T Beaume-Six; G Dureau; P J Meunier
Journal:  Osteoporos Int       Date:  1993-12       Impact factor: 4.507

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.